The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors.

Classical studies using bovine chromaffin granules have defined the physiologic and pharmacologic properties of the vesicular amine transporter that packages monoamine transmitters into intracellular vesicles for subsequent regulated release. The recent isolation of two distinct but closely related cDNA clones encoding vesicular amine transport suggests that the activity expressed in the brain (synaptic vesicle amine transporter or SVAT) may differ significantly from the previously described adrenal gland activity (chromaffin granule amine transporter or CGAT). A direct comparison of the two transporters now shows that SVAT has a higher affinity than CGAT for monoamine substrates, in particular for histamine. In addition, SVAT shows approximately 10-fold greater sensitivity to tetrabenazine than CGAT. [3H]Dihydrotetrabenazine shows no detectable binding to CGAT but does bind to SVAT, accounting for the differential sensitivity. Furthermore, methamphetamine preferentially inhibits transport by SVAT relative to CGAT, apparently by competing at the site of amine recognition rather than by disrupting the vesicular pH gradient. These previously unsuspected differences in the storage of monoamine transmitter in the central nervous system and the adrenal gland may help to account for several classic pharmacological observations.

• Publication year

  1994

• Venue

  Journal of Biological Chemistry

• Publication date

  1994-03-11

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/s0021-9258(17)37272-1PMID 8125935
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neurotransmitter transporters: recent progress.

  1993cited by this paper
• Non-neurotoxic amphetamine derivatives release serotonin through serotonin transporters.

  1993cited by this paper
• Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblasts.

  1993cited by this paper
• Gene transfer of a reserpine-sensitive mechanism of resistance to N-methyl-4-phenylpyridinium.

  1992cited by this paper
• The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.

  1992cited by this paper
• A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter.

  1992cited by this paper
• p-Chloroamphetamine induces serotonin release through serotonin transporters.

  1992cited by this paper
• Expression cloning of a reserpine-sensitive vesicular monoamine transporter.

  1992cited by this paper
• Proteins of synaptic vesicles involved in exocytosis and membrane recycling.

  1991cited by this paper
• Cellular and molecular biology of the presynaptic nerve terminal.

  1991cited by this paper
• Evidence that the blockade of mitochondrial respiration by the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) involves binding at the same site as the respiratory inhibitor, rotenone.

  1990cited by this paper
• Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action.

  1990cited by this paper
• Induction of the vesicular monoamine transporter by elevated potassium concentration in cultures of rat sympathetic neurons.

  1990cited by this paper
• Pathways to regulated exocytosis in neurons.

  1990cited by this paper
• Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine transporter.

  1990cited by this paper
• Identification and purification of a functional amine transporter from bovine chromaffin granules.

  1990cited by this paper
• Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles.

  1989cited by this paper
• Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats.

  1989cited by this paper
• Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter.

  1989cited by this paper
• Glutamate uptake by brain synaptic vesicles. Energy dependence of transport and functional reconstitution in proteoliposomes.

  1988cited by this paper
• Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport.

  1988cited by this paper
• Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles.

  1988cited by this paper
• Time required for transmitter accumulation inside monoaminergic storage vesicles differs in peripheral and in central systems.

  1988cited by this paper
• Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats.

  1988cited by this paper
• Mechanism of transport and storage of neurotransmitters.

  1987cited by this paper
• MPTP: A neurotoxin producing a parkinsonian syndrome

  1987cited by this paper
• Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria.

  1986cited by this paper
• Dihydrotetrabenazine Binding and Monoamine Uptake in Mouse Brain Regions

  1986cited by this paper
• Pharmacological basis of therapeutics: dopamine receptors.

  1984cited by this paper
• Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding.

  1984cited by this paper
• EFFECT OF NEUROLEPTICS AND OTHER DRUGS ON MONOAMINE UPTAKE BY MEMBRANES OF ADRENAL CHROMAFFIN GRANULES

  1977cited by this paper
• A new technique for the assay of infectivity of human adenovirus 5 DNA.

  1973cited by this paper

• Evidence for low affinity of GABA at the vesicular monoamine transporter VMAT2 - implications for transmitter co-release from dopamine neurons.

  2025cites this paper
• Molecular basis of vesicular monoamine transport and neurological drug interactions

  2025cites this paper
• Drug inhibition and substrate transport mechanisms of human VMAT2

  2025cites this paper
• Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta

  2024cites this paper
• Structural insights into vesicular monoamine storage and drug interactions

  2024cites this paper
• Packaging monoamine neurotransmitters

  2024cites this paper
• Determination of metal ion transport rate of human ZIP4 using stable zinc isotopes

  2024cites this paper
• Structural mechanisms for VMAT2 inhibition by tetrabenazine

  2024cites this paper
• Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta

  2024cites this paper
• Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2

  2023cites this paper
• Structural mechanisms for VMAT2 inhibition by tetrabenazine

  2023cites this paper
• Divergent properties and independent regulation of striatal dopamine and GABA co-transmission

  2022cites this paper
• Impact of Environmental Risk Factors on Mitochondrial Dysfunction, Neuroinflammation, Protein Misfolding, and Oxidative Stress in the Etiopathogenesis of Parkinson’s Disease

  2022cites this paper
• Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone

  2022cites this paper
• Effects of the GluN2B-selective antagonist Ro 63-1908 on acquisition and expression of methamphetamine conditioned place preference in male and female rats.

  2021cites this paper
• Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity

  2021cites this paper
• Molecular, Structural, Functional, and Pharmacological Sites for Vesicular Glutamate Transporter Regulation

  2020cites this paper
• Balance alterations and reduction of pedunculopontine cholinergic neurons in early stages of parkinsonism in middle-aged rats.

  2020cites this paper
• Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Changes to Astrocyte Structure and Function

  2020cites this paper
• Molecular Mechanisms of Amphetamines.

  2019cites this paper
• The Druggability of Solute Carriers.

  2019cites this paper
• Functional Compounds of Lobelia inflata Revealed Novel Potential Targets for Chronic Cough Therapy

  2019cites this paper
• VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine).

  2018cites this paper
• FUNCTIONAL AND BIOCHEMICAL CONSEQUENCES OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE HUMAN VESICULAR MONOAMINE TRANSPORTER 1 GENE ( SLC 18 A 1 )

  2018cites this paper
• The ins and outs of vesicular monoamine transporters

  2018influential citation
• Natural Molecules From Chinese Herbs Protecting Against Parkinson’s Disease via Anti-oxidative Stress

  2018cites this paper
• New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders

  2018cites this paper
• MECHANISMS OF VESICULAR MONOAMINE TRANSPORTER-2 DEGRADATION

  2017cites this paper
• Current understanding of methamphetamine-associated dopaminergic neurodegeneration and psychotoxic behaviors

  2017cites this paper
• Membrane transporters as mediators of synaptic dopamine dynamics: implications for disease

  2017influential citation
• Kirsi Mikkola VMAT 2 AND GLP-1 R TARGETING TRACERS FOR PANCREATIC BETA CELL IMAGING

  2017cites this paper
• Clathrin-Dependent Uptake of Paraquat into SH-SY5Y Cells and Its Internalization into Different Subcellular Compartments

  2017cites this paper
• Mechanisms of Autoreceptor-Mediated Inhibition in Central Monoamine Neurons

  2016cites this paper
• Effects of oxytocin on adreno-medullary catecholamine synthesis, uptake and storage in rats exposed to chronic isolation stress

  2016cites this paper
• PROBING SECRETORY VESICLES AND LIPOSOME MODEL SYSTEMS USING NANOSCALE ELECTROCHEMISTRY AND MASS SPECTROMETRY

  2016influential citation
• Role for Reactive Oxygen Species in Methamphetamine Modulation of Dopamine Release in the Striatum

  2016cites this paper
• Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis

  2016influential citation
• SLC10A4 is a vesicular amine-associated transporter modulating dopamine homeostasis.

  2015cites this paper
• Mutation in VMAT2 Causing a Pediatric Neurotransmitter Disease

  2015cites this paper
• Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

  2015cites this paper
• Molecular, Neurochemical, and Behavioral Hallmarks of Reserpine as a Model for Parkinson's Disease: New Perspectives to a Long‐Standing Model

  2015cites this paper
• Vesicular Amine Transporter VMAT2 in the Rat Ileum: from Principal Mechanism to Clinical Applications

  2015influential citation
• Design, synthesis, and pharmacological evaluation of three series of lobelane analogs as inhibitors of the vesicular monoamine transporter (VMAT2)

  2015influential citation
• The Role of E3 Ligase Parkin in Trafficking of Monoamine Storage Vesicles in Rat Model of Methamphetamine Neurotoxicity

  2015cites this paper
• Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease

  2015cites this paper
• Amphetamines, new psychoactive drugs and the monoamine transporter cycle

  2014cites this paper
• The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.

  2014cites this paper
• LOBELANE ANALOGS WITH VARIOUS METHYLENE LINKER LENGTHS AND ACYCLIC LOBELANE ANALOGS AS POTENTIAL PHARMACOTHERAPIES TO TREAT METHAMPHETAMINE ABUSE

  2014influential citation
• Nuevas drogas psicoestimulantes. Estudio farmacológico y neurotoxicológico de la metilona

  2014cites this paper
• Two opposing serotonergic neuronal circuits modulate ethanol preference of Drosophila melanogaster

  2014cites this paper
• Origins of the sympathetic innervation to the nasal-associated lymphoid tissue (NALT): an anatomical substrate for a neuroimmune connection.

  2014cites this paper
• Two opposing serotonergic neuronal circuits modulate ethanol preference of Drosophila melanogaster

  2013cites this paper
• DIET-INDUCED OBESITY: DOPAMINERGIC AND BEHAVIORAL MECHANISMS AS OUTCOMES AND PREDICTORS

  2013cites this paper
• New fluorescent substrate enables quantitative and high-throughput examination of vesicular monoamine transporter 2 (VMAT2).

  2013cites this paper
• Transport Mechanisms of the Vesicular Glutamate Transporter 1

  2013cites this paper
• Chapter 3 Histamine Metabolism

  2013cites this paper
• Évaluation fonctionnelle par TEP 18F-FDopa des paragangliomes et phéochromocytomes non métastatiques : impact de la localisation lésionnelle et du statut génétique

  2013cites this paper
• Neural substrates of amphetamine induced impulsive behaviour

  2013cites this paper
• Histamine Metabolism

  2013influential citation
• Progress Towards Understanding Of Mechanisms Of Action Of Potent Multifunctional Disease Modifying Therapeutics For Parkinson's Disease & Investigating The Methamphetamine-Induced Striatal Microglia Activation.

  2013cites this paper
• Mechanisms of dopamine quantal size regulation.

  2012cites this paper
• [Breast implant scandal shows weaknesses in the European information practice].

  2012cites this paper
• Vesicular and plasma membrane transporters for neurotransmitters.

  2012cites this paper
• Distributional characteristics of vesicular monoamine transporter 2 in human embryonic brain and their correlation with Parkinson's disease

  2012cites this paper
• DISCOVERY OF GZ-793A, A NOVEL VMAT2 INHIBITOR AND POTENTIAL PHARMACOTHERAPY FOR METHAMPHETAMINE ABUSE

  2012influential citation
• FUNCTIONAL AND BIOCHEMICAL CONSEQUENCES OF SINGLE NUCLEOTIDE POLYMORPHISMS IN THE HUMAN VESICULAR MONOAMINE TRANSPORTER 1 GENE (SLC18A1)By Sally Gamal Shukry, B.S.

  2012cites this paper
• Caractérisations biochimique anatomique et comportementale des souris dépourvues de la protéines STOP : un modèle expérimental pour l'étude de symptômes psycho-affectifs

  2011cites this paper
• The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.

  2011influential citation
• Vesicular monoamine transporter-1 (VMAT-1) mRNA and immunoreactive proteins in mouse brain.

  2011cites this paper
• Regulation der Monoamin- und Glutamatspeicherung in sekretorischen Vesikeln durch die Go2alpha-Untereinheit heterotrimerer G-Proteine

  2011influential citation
• Vesicular monoamine transporters: Structure‐function, pharmacology, and medicinal chemistry

  2011cites this paper
• VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease

  2011cites this paper
• How addictive drugs disrupt presynaptic dopamine neurotransmission.

  2011cites this paper
• Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse.

  2011cites this paper
• Stress Triggered Changes in Expression of Genes for Neurosecretory Granules in Adrenal Medulla

  2011cites this paper
• Effect of SA 4503 on the locomotor stimulatory and discriminative stimulus properties of psychostimulants

  2010cites this paper
• Expression of neurotransmitter transporters for structural and biochemical studies.

  2010cites this paper
• 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.

  2010cites this paper
• Vesicular Monoamine Transporters (VMATs) in Adrenal Chromaffin Cells: Stress-Triggered Induction of VMAT2 and Expression in Epinephrine Synthesizing Cells

  2010cites this paper
• Intrinsic choroidal neurons in the chicken eye: chemical coding and synaptic input

  2010cites this paper
• Assessment of Islet Specificity of Dihydrotetrabenazine Radiotracer Binding in Rat Pancreas and Human Pancreas

  2010cites this paper
• Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa.

  2009cites this paper
• MOLECULAR CLONING AND CHARACTERIZATION OF A VESICULAR ACETYLCHOLINE TRANSPORTER FROM ONCHOCERCA VOLVULUS AND ITS BIOCHEMICAL CHARACTERIZATION IN HAEMONCHUS CONTORTUS

  2009cites this paper
• 7 Vesicular Neurotransmitter Transporters

  2009cites this paper
• Directed Evolution Reveals Hidden Properties of VMAT, a Neurotransmitter Transporter*

  2009cites this paper
• Contribution of vesicular and cytosolic dopamine to the increased striatal dopamine efflux elicited by intrastriatal injection of SKF38393.

  2009cites this paper
• Amphetamine reduces vesicular dopamine content in dexamethasone‐differentiated PC12 cells only following l‐DOPA exposure

  2009influential citation
• Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances.

  2008cites this paper
• The Role of Glutamate Transporters in Synaptic Transmission

  2008cites this paper
• Changing the copy number of transmitter transporters per vesicle - sorting versus expression under regime of day-night cycle

  2008cites this paper
• monoamine transporter 2 Expression and function of the rat vesicular

  2008cites this paper
• Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias.

  2008influential citation
• Synaptic Vesicle Protein 2 Binds Adenine Nucleotides*

  2008cites this paper
• Expression and function of the rat vesicular monoamine transporter 2.

  2008cites this paper
• Pharmacology of neurotransmitter transport into secretory vesicles.

  2008cites this paper
• The Vesicular Monoamine Transporter

  2008cites this paper
• Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat

  2007influential citation
• Thyronamines inhibit plasma membrane and vesicular monoamine transport.

  2007cites this paper
• The neurotransmitter cycle and quantal size.

  2007cites this paper
• From chromaffin cells to Phaeochromocytoma: insight into the sympathoadrenal cell lineage

  2007cites this paper